Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dewald Felix, Pirkl Martin, Paluschinski Martha, Kühn Joachim, Elsner Carina, Schulte Bianca, Knüfer Jacqueline, Ahmadov Elvin, Schlotz Maike, Oral Göksu, Bernhard Michael, Michael Mark, Luxenburger Maura, Andrée Marcel, Hennies Marc Tim, Hafezi Wali, Müller Marlin Maybrit, Kümpers Philipp, Risse Joachim, Kill Clemens, Manegold Randi Katrin, von Frantzki Ute, Richter Enrico, Emmert Dorian, Monzon-Posadas Werner O, Gräff Ingo, Kogej Monika, Büning Antonia, Baum Maximilian, Teipel Finn, Mochtarzadeh Babak, Wolff Martin, Gruell Henning, Di Cristanziano Veronica, Burst Volker, Streeck Hendrik, Dittmer Ulf, Ludwig Stephan, Timm Jörg, Klein Florian
Аннотация
Determining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need for prevention and mitigation strategies. We measured SARS-CoV-2 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01, BA.4/5 and BQ.1.1 in a convenience sample of 1,411 patients receiving medical treatment in the emergency departments of five university hospitals in North Rhine-Westphalia, Germany, in August/September 2022. 62% reported underlying medical conditions and 67.7% were vaccinated according to German COVID-19 vaccination recommendations (13.9% fully vaccinated, 54.3% one booster, 23.4% two boosters). We detected Spike-IgG in 95.6%, Nucleocapsid-IgG in 24.0%, and neutralization against Wu01, BA.4/5 and BQ.1.1 in 94.4%, 85.0%, and 73.8% of participants, respectively. Neutralization against BA.4/5 and BQ.1.1 was 5.6- and 23.4-fold lower compared to Wu01. Accuracy of S-IgG detection for determination of neutralizing activity against BQ.1.1 was reduced substantially. We explored previous vaccinations and infections as correlates of BQ.1.1 neutralization using multivariable and Bayesian network analyses. Given a rather moderate adherence to COVID-19 vaccination recommendations, this analysis highlights the need to improve vaccine-uptake to reduce the COVID-19 risk of immune evasive variants. The study was registered as clinical trial (DRKS00029414).